--- a
+++ b/clusters/9knumclustersv2/clust_1330.txt
@@ -0,0 +1,26 @@
+Use of other investigational drugs at the time of screening or within the last  days.
+Subjects may not receive any other concomitant investigational agents
+Concomitant use of any anticancer therapy or use of any investigational agent(s).
+Concomitant use of other cytotoxic or cytostatic drugs other than PTX
+Concomitant use of other investigational agents.
+Use of any investigational drugs within  days prior to dosing
+Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
+Concomitant use of other investigational agents
+Use of other investigational drugs
+Concomitant use of any other investigational drugs
+Concomitant use of any other investigational or anticancer agent(s).
+Concomitant use of other investigational agents
+Prior use of investigational drugs =<  days prior to registration
+Concomitant use of any other investigational drugs
+Concomitant use of any other investigational drugs
+Subjects may not receive any other concomitant investigational agents
+Subjects receiving concomitant treatment with radiotherapy or other investigational drugs
+Concomitant use of any other investigational drugs
+Use of other investigational drugs
+Serious uncontrolled concomitant disease that would contraindicate the use of any of the investigational drugs used in this study or would put the participants at high risk for treatment-related complications
+Use of anti-cancer treatment (including investigational drugs) within  days
+Use of investigational drugs within  weeks of signing consent or foreseen use during the study
+Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug [IND] for initial efficacy investigations)
+Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an investigational new drug (IND) for initial efficacy investigations
+Concomitant investigational therapy
+Concomitant investigational therapy